Amorphous solid dispersions stabilized by one or more polymer (s) have been widely used
for delivering amorphous drugs with poor water solubilities, and they have gained great …

Formulating poorly soluble molecules as amorphous solid dispersions (ASDs) is an effective
strategy to improve drug release. However, drug release rate and extent tend to rapidly …

Enteric polymers are widely used in amorphous solid dispersion (ASD) formulations. The
aim of the current study was to explore ASD failure mechanisms across a wide range of pH …

In this work, an important step is taken towards the bioavailability improvement of poorly
water-soluble drugs, such as flubendazole (Flu), posing a challenge in the current …

Along with the increasing demand for complex formulations comes the need for appropriate
in vitro methodologies capable of predicting their corresponding in vivo performance and the …

Along with the increasing demand for candidate-enabling formulations comes the need for
appropriate in vitro bioavailability forecasting. Dissolution/permeation (D/P) systems …

In this work, the feasibility of ultra-high drug loaded amorphous solid dispersions (ASDs) for
the poorly soluble itraconazole, mebendazole and celecoxib via solvent electrospinning in …

The in-situ formation of nanoparticles from polymer-based solid medicines, although
previously described, has been overlooked despite its potential to interfere with oral drug …

Purpose Amorphous solid dispersions (ASD) for nasal delivery offer the opportunity to
increase drug release performance, while using polymers with mucoadhesive properties …

Recent work has highlighted that amorphous solid dispersions (ASDs) containing
delamanid (DLM) and an enteric polymer, hypromellose phthalate (HPMCP), appear to be …